1250 - Testing of the ALK gene in tumour material from patients with non-small cell lung cancer to determine eligibility for treatment with crizotinib

Page last updated: 11 July 2016

Application Detail

Status

Closed

Description of Medical Service

ALK FISH testing identifies tumours that carry the ALK rearrangement obtained from patients with advanced NSCLC. Subsidy from the Pharmaceutical Benefits Scheme is also being sought for crizotinib for the treatment of patients with the ALK rearrangement.

Description of Medical Condition

ALK-positive advanced NSCLC.

Reason for Application

-

Medical Service Type

-

Previous Application Number

Not Applicable

Associated Documentation

Application Form

-

PICO Confirmation

28 May 2012 – 5 July 2012
Consultation Decision Analytic Protocol (DAP) (PDF 250 KB)
Consultation Decision Analytic Protocol (DAP) (Word 740 KB)

Final Decision Analytic Protocol (DAP) (PDF 585 KB)
Final Decision Analytic Protocol (DAP) (Word 6128 KB)

Assessment Report

-

Public Summary Document

Public Summary Document (PDF 247 KB)
Public Summary Document (Word 150 KB)

Meetings for this Application

PASC

12 – 13 April 2012
16 – 17 August 2012

ESC

10 – 11 October 2013

MSAC

28 November 2013